Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject was diagnosed with chronic plaque psoriasis at least 6 months before randomisation.~* Subject has a diagnosis of moderate-to-severe plaque psoriasis as defined by PASI ≥12, sPGA ≥3, and body surface area ≥10% at screening and at baseline.~* Subject, in whom topical therapy is not adequate, and who is a candidate for systemic therapy.~* Subject has no evidence of active or latent tuberculosis according to local standard of care.~Key Exclusion Criteria:~* Subject is diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions (e.g., eczema).~* Subject has been vaccinated with a tetanus toxoid-containing vaccine ≤18 months prior to first dose of investigational medicinal product (IMP). For EU and UK: Subject has been vaccinated with a TT-containing vaccine within 5 years prior to the first dose of IMP.~* Subject has developed or experienced either Guillian-Barre syndrome, encephalopathy, Arthus-type hypersensitivity, or severe allergic reactions in connection with previous Tdap or Td vaccine.~* Subject with chronic or recurrent infections, or active infection, systemically treated within 4 weeks prior to first dose of IMP.~* Subject has a known history of Crohn's disease.~* Subject has any active malignancy or a history of any malignancy within 5 years.~* Subject has a history of suicidal behaviour and has suicidal ideation with some intent to act or specific plan and intent.~* Subject has a history of depressive disorder with severe episode(s) within the last 2 years.~* Subject has received anti-IL-12/23p40 for less than 12 months prior to the first dose of IMP or has previously no response to anti-IL-12/23p40 therapy.~* Subject has previously received anti-IL-17 therapy.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Brodalumab (Type: EXPERIMENTAL): Brodalumab for 52 weeks. The dose will be determined by the participant's body weight.
- Ustekinumab (Type: ACTIVE_COMPARATOR): Ustekinumab for 52 weeks. The dose will be determined by the participant's body weight.
- Placebo/brodalumab (Type: PLACEBO_COMPARATOR): Placebo for the first 12 weeks and brodalumab for the following 40 weeks. The dose will be determined by the participant's body weight.
- Placebo/ustekinumab (Type: PLACEBO_COMPARATOR): Placebo for the first 12 weeks and ustekinumab for the following 40 weeks. The dose will be determined by the participant's body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).